Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin in Chinese T2D Patients on Metformin +/- Sulfonylurea
NCT03761134Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sotagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoint: Change in hemoglobin A1c at 24 weeks. Started Nov 2018; status: terminated.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03761134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03761134.